Abstract
In the last 20-30 years the approach to metastatic breast cancer by chemotherapy has been largely studied. Anthracyclines, taxanes and, more recently, capecitabine and gemcitabine represent the breakthrough of treatment. In the next future the combination of chemotherapy and target therapy will be considered more frequently.
| Original language | English |
|---|---|
| Journal | Annals of Oncology |
| Volume | 17 |
| Issue number | SUPPL. 5 |
| DOIs | |
| Publication status | Published - May 2006 |
Fingerprint
Keywords
- Chemotherapy
- Metastatic breast cancer
- Trastuzumab
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
First line chemotherapy of metastatic breast cancer. / Pronzato, P.; Rondini, M.
In: Annals of Oncology, Vol. 17, No. SUPPL. 5, 05.2006.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - First line chemotherapy of metastatic breast cancer
AU - Pronzato, P.
AU - Rondini, M.
PY - 2006/5
Y1 - 2006/5
N2 - In the last 20-30 years the approach to metastatic breast cancer by chemotherapy has been largely studied. Anthracyclines, taxanes and, more recently, capecitabine and gemcitabine represent the breakthrough of treatment. In the next future the combination of chemotherapy and target therapy will be considered more frequently.
AB - In the last 20-30 years the approach to metastatic breast cancer by chemotherapy has been largely studied. Anthracyclines, taxanes and, more recently, capecitabine and gemcitabine represent the breakthrough of treatment. In the next future the combination of chemotherapy and target therapy will be considered more frequently.
KW - Chemotherapy
KW - Metastatic breast cancer
KW - Trastuzumab
UR - http://www.scopus.com/inward/record.url?scp=33745594833&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745594833&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdj974
DO - 10.1093/annonc/mdj974
M3 - Article
VL - 17
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - SUPPL. 5
ER -